Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc. (NYSE: INSP) develops and commercializes minimally invasive treatments for obstructive sleep apnea (OSA), principally its implantable Inspire system for patients with moderate to severe OSA who cannot tolerate or do not benefit from positive airway pressure therapy. The closed-loop system… From the company’s description.
Over the twelve months to Sep 30, 2026, Inspire Medical Systems, Inc. reported revenue of $880.94M, down 0.2% from a year earlier, and net income of $100.72M. Its operating margin was 1.8%, and operations generated $134.97M in cash. In fiscal 2025, it reported revenue of $911.98M, up 13.6% from fiscal 2024, and net income of $145.42M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Inspire Medical Systems, Inc. does
In the company’s own words
Inspire Medical Systems, Inc. (NYSE: INSP) develops and commercializes minimally invasive treatments for obstructive sleep apnea (OSA), principally its implantable Inspire system for patients with moderate to severe OSA who cannot tolerate or do not benefit from positive airway pressure therapy. The closed-loop system monitors breathing and stimulates the hypoglossal nerve to help keep the airway open during sleep. Inspire sells to hospitals and ambulatory surgery centers in the United States and select European markets through its direct sales organization, and uses distributors in Japan, Singapore, Hong Kong, and Thailand. Its customers include healthcare facilities and providers, while treatment is generally reimbursed by commercial insurers and government programs. The company reports one operating business focused on Inspire therapy; related products include the Inspire IV and V systems, the SleepSync patient management platform, and the Inspire Sleep app. Inspire therapy has been commercially available in Europe since 2011 and received U.S. FDA approval in 2014; the business originated as a spin-off from Medtronic in 2007. Physicians have treated more than 125,000 patients with the therapy across the United States, Europe, and Asia. Its website is https://www.inspiresleep.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- GOLDEN VALLEY, MN
- Fiscal year end
- December
- CIK
- 1609550
- SIC
- 3841
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Inspire Medical Systems, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Inspire Medical Systems, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Inspire Medical Systems, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Inspire Medical Systems, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Inspire Medical Systems, Inc.'s last four quarterly filings that the numbers alone won't show?”